

441  
Cgy

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Jun 03 New e-mail delivery for search results now available  
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 11 Oct 24 BEILSTEIN adds new search fields  
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 20 EVENTLINE will be removed from STN  
NEWS 28 Mar 24 PATDPAFULL now available on STN  
NEWS 29 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 30 Apr 11 Display formats in DGENE enhanced  
NEWS 31 Apr 14 MEDLINE Reload  
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 33 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS  
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX  
NEWS 35 Apr 28 RDISCLOSURE now available on STN  
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names  
added to PHAR  
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded  
NEWS 38 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated  
NEWS 39 May 16 CHEMREACT will be removed from STN  
NEWS 40 May 19 Simultaneous left and right truncation added to WSCA

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:51:47 ON 20 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:51:59 ON 20 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10077150.9

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,NH

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 12:52:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 32516 TO ITERATE

3.1% PROCESSED 1000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
 BATCH \*\*INCOMPLETE\*\*  
 PROJECTED ITERATIONS: 639572 TO 661068  
 PROJECTED ANSWERS: 308 TO 992

L2 1 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 12:52:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 648466 TO ITERATE

61.7% PROCESSED 400000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.11

174 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
 BATCH \*\*INCOMPLETE\*\*  
 PROJECTED ITERATIONS: 648466 TO 648466  
 PROJECTED ANSWERS: 232 TO 332

L3 174 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:52:52 ON 20 MAY 2003

Patel

&lt;5/19/2003&gt;

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2003 VOL 138 ISS 21  
FILE LAST UPDATED: 19 May 2003 (20030519/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 41 L3

=> s l4 and CFR

L5 0 L4 AND CFR

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 2002:964355 CAPLUS

DN 138:55951

TI Preparation of 1-(2,1,3-benzothiadiazolyl)-3-pyridylpropyl-1,8-naphthyridine derivatives as phosphodiesterase (PDE) IV inhibitors

IN Aotsuka, Tomoji; Kumazawa, Kentarou; Wagatsuma, Nagatoshi; Ishitani, Kouki; Nose, Takashi

PA Grelan Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100859	A1	20021219	WO 2002-JP5804	20020611
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2001-176550 A	20010612

OS MARPAT 138:55951

IT 479073-54-6P 479073-55-7P 479073-56-8P


479073-57-9P 479073-58-0P 479073-59-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of (benzothiadiazolyl)(pyridylpropyl)naphthyridine derivs. as PDE IV inhibitors)


RN 479073-54-6 CAPLUS

CN 3-Pyridinecarboxaldehyde, 2-(2,1,3-benzothiadiazol-5-ylamino)- (9CI) (CA INDEX NAME)




RN 479073-55-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(2,1,3-benzothiadiazol-5-ylamino)- (9CI) (CA INDEX NAME)




RN 479073-56-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(2,1,3-benzothiadiazol-5-ylamino)-, cyanomethyl ester (9CI) (CA INDEX NAME)




RN 479073-57-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(2,1,3-benzothiadiazol-5-ylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 479073-58-0 CAPLUS

CN 3-Pyridinemethanol, 2-(2,1,3-benzothiadiazol-5-ylamino)- (9CI) (CA INDEX NAME)




RN 479073-59-1 CAPLUS


CN 3-Pyridinecarboxaldehyde, 2-(2,1,3-benzothiadiazol-4-ylamino)- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. I [wherein A = CH<sub>2</sub>, alkyl-CH<sub>2</sub>, CO, HOCH<sub>2</sub>, or alkyl-CO<sub>2</sub>CH<sub>2</sub>; Y = heteroaryl; Z = heteroaryl or (un)substituted Ph] and pharmaceutically acceptable salts thereof are prepd as PDE IV inhibitors for the treatment of asthma. For example, 2-(3-nitrophenylamino)nicotinaldehyde (prepn given) was reacted with Et 5-methyl-5-(pyrid-4-yl)pentanoate (prepn given) in THF in the presence of LDA to afford the naphthyridine II (37%). II showed IC<sub>50</sub> of 0.070 .mu.M against PDE IV and ED<sub>50</sub> of 0.12 mg/kg against asthma in guinea pig.

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 2002:886244 CAPLUS

DN 137:371475

TI Anthrapyridones or their salts and their aqueous magenta inks with good ozone and light resistance for jet printers

IN Kato, Yoshinori; Fujii, Takafumi; Kitayama, Hirokazu; Matsumoto, Hiroyuki; Shirasaki, Yasuo

PA Nippon Kayaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2002332419	A2	20021122	JP 2001-138113	20010509
				JP 2001-138113	20010509

OS MARPAT 137:371475

IT **475589-96-9P 475590-00-2P 475590-03-5P**


**475590-06-8P**

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(anthrapyridones for aq. magenta jet inks with good ozone and light resistance)


RN 475589-96-9 CAPLUS

CN 2H-Benzotriazole-5-sulfonic acid, 6-[[6-[[3-[(2,7-dihydro-3-methyl-2,7-dioxo-3H-naphtho[1,2,3-de]quinolin-6-yl)amino]-4-sulfophenyl]amino]-1,4-dihydro-4-oxo-1,3,5-triazin-2-yl]amino]-2-(4-sulfophenyl)- (9CI) (CA INDEX NAME)




RN 475590-00-2 CAPLUS

CN 1,4-Benzenedisulfonic acid, 2-[5-[[6-[[3-[(2,7-dihydro-3-methyl-2,7-dioxo-3H-naphtho[1,2,3-de]quinolin-6-yl)amino]-4-sulfophenyl]amino]-1,4-dihydro-4-oxo-1,3,5-triazin-2-yl]amino]-6-sulfo-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




RN 475590-03-5 CAPLUS

CN Benzoic acid, 2-[5-[[6-[[3-[(2,7-dihydro-3-methyl-2,7-dioxo-3H-naphtho[1,2,3-de]quinolin-6-yl)amino]-4-sulfophenyl]amino]-1,4-dihydro-4-oxo-1,3,5-triazin-2-yl]amino]-6-sulfo-2H-benzotriazol-2-yl]-4-sulfo- (9CI) (CA INDEX NAME)




RN 475590-06-8 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[5-[[6-[[3-[(2,7-dihydro-3-methyl-2,7-dioxo-3H-naphtho[1,2,3-de]quinolin-6-yl)amino]-4-sulfophenyl]amino]-1,4-dihydro-4-oxo-1,3,5-triazin-2-yl]amino]-6-sulfo-2H-benzotriazol-2-yl]-9CI) (CA INDEX NAME)




GI



I

AB The invention relates to anthrapyridones or their salts I (R1 = H, alkyl, cyclohexyl, alkylaminoalkyl, etc.; R2, R3 = H, alkyl, alkoxy, sulfonic, carboxyl; X = aryl; Y = Cl, OH, amino, alkoxy, anilino, etc.). Thus, an aq. jet ink contg. I (R1 = Me, R2 = SO3H, X = 4-sulfophenyl, Y = OH) showed good color images.

L4 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:507825 CAPLUS  
 DN 137:325929  
 TI Synthesis and properties of new adducts of 2,2,6,6-tetramethylpiperidine and 2-hydroxyphenylbenzotriazole as polymer photostabilizers  
 AU Bojinov, Vladimir; Grabchev, Ivo  
 CS Organic Synthesis Department, University of Chemical Technology and Metallurgy, Sofia, 1756, Bulg.  
 SO Journal of Photochemistry and Photobiology, A: Chemistry (2002), 150(1-3), 223-231  
 CODEN: JPPCEJ; ISSN: 1010-6030  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 IT **153976-86-4P 153976-87-5P 451470-91-0P**  
**473576-31-7P 473576-32-8P 473576-33-9P**  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and properties of adducts of 2,2,6,6-tetramethylpiperidine and 2-hydroxyphenylbenzotriazole as polymerizable photostabilizers)  
 RN 153976-86-4 CAPLUS  
 CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




RN 153976-87-5 CAPLUS

Patel


<5/19/2003>

CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




RN 451470-91-0 CAPLUS

CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 473576-31-7 CAPLUS


CN Phenol, 2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



RN 473576-32-8 CAPLUS


CN Phenol, 4-chloro-2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)





RN 473576-33-9 CAPLUS

CN Phenol, 4-nitro-2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



IT 230302-42-8P 230302-43-9P 451470-98-7P

473576-35-1P 473576-36-2P 473576-37-3P

473576-38-4P 473576-39-5P 473576-40-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and properties of adducts of 2,2,6,6-tetramethylpiperidine  
and 2-hydroxyphenylbenzotriazole as polymerizable photostabilizers)


RN 230302-42-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 153976-86-4


CMF C18 H14 Cl N7 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 230302-43-9 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 451470-98-7 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]-4-nitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 451470-91-0


CMF C18 H13 Cl N8 O4



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 473576-35-1 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-  
 triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 473576-31-7


CMF C27 H32 N8 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2



RN 473576-36-2 CAPLUS


CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 4-chloro-2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-

1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 473576-32-8


CMF C27 H31 Cl N8 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 473576-37-3 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with 4-nitro-2-[5-[[4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 473576-33-9


CMF C27 H31 N9 O4



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 473576-38-4 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-chloro-4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-  
triazine and 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-  
2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 219320-49-7


CMF C15 H23 Cl N4 O



CM 2

CRN 153976-86-4


CMF C18 H14 Cl N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 473576-39-5 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]phenol and 2-chloro-4-(2-propenyloxy)-6-(2,2,6,6-  
 tetramethyl-1-piperidinyl)-1,3,5-triazine (9CI) (CA INDEX NAME)

CM 1

CRN 219320-49-7


CMF C15 H23 Cl N4 O



CM 2

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 473576-40-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-chloro-4-(2-propenyloxy)-6-(2,2,6,6-tetramethyl-1-piperidinyl)-1,3,5-  
 triazine and 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-  
 2H-benzotriazol-2-yl]-4-nitrophenol (9CI) (CA INDEX NAME)


CM 1

CRN 451470-91-0  
CMF C18 H13 Cl N8 O4




CM 2

CRN 219320-49-7  
CMF C15 H23 Cl N4 O



CM 3

CRN 80-62-6  
CMF C5 H8 O2




AB The synthesis of new stabilizer type compds. (a combination between 2,2,6,6-tetramethylpiperidine and 2-hydroxyphenylbenzotriazole in one mol.) is reported. Three new polymerizable combined stabilizers as well as one unsatd. triazinyl-2,2,6,6-tetramethylpiperidine and three unsatd. triazinyl-2-hydroxyphenylbenzotriazoles as individual stabilizers were synthesized. Their copolymers and the terpolymers of the individual stabilizers with Me methacrylate (MMA) were obtained. Chem. bonding of the stabilizers in the polymer was confirmed spectrophotometrically. The influence of these additives on the photostability of the copolymers was studied. The participation of the combined stabilizers in the polymn. did not affect considerably the rate of copolymn., the mol. wt. and polydispersity of the copolymers. A significant stabilizing effect against photodegrdn. was detd.


RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:371737 CAPLUS  
DN 137:186312  
TI Synthesis and properties of adducts of a hindered amine and  
2-hydroxyphenylbenzotriazole as novel polymer stabilizers  
AU Bojinov, Vladimir  
CS Organic Synthesis Department, University of Chemical Technology and  
Metallurgy, Sofia, 1756, Bulg.  
SO Photochemical & Photobiological Sciences (2002), 1(5), 340-346  
CODEN: PPSHCB; ISSN: 1474-905X  
PB Royal Society of Chemistry  
DT Journal  
LA English  
IT 153976-86-4P 153976-87-5P 451470-91-0P  
451470-92-1P 451470-93-2P 451470-94-3P  
451470-95-4P 451470-96-5P 451470-97-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and properties of adducts of hindered amine and  
2-hydroxyphenylbenzotriazole as polymer stabilizers)  
RN 153976-86-4 CAPLUS  
CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



RN 153976-87-5 CAPLUS  
CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




RN 451470-91-0 CAPLUS  
CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 451470-92-1 CAPLUS

CN Phenol, 2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl] - (9CI)  
(CA INDEX NAME)




RN 451470-93-2 CAPLUS

CN Phenol, 4-chloro-2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl] - (9CI)  
(CA INDEX NAME)




RN 451470-94-3 CAPLUS

CN Phenol, 4-nitro-2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl] - (9CI)  
(CA INDEX NAME)




RN 451470-95-4 CAPLUS

CN Phenol, 2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-(9CI) (CA INDEX NAME)




RN 451470-96-5 CAPLUS

CN Phenol, 4-chloro-2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-(9CI) (CA INDEX NAME)



RN 451470-97-6 CAPLUS

CN Phenol, 4-nitro-2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-(9CI) (CA INDEX NAME)



IT 230302-42-8P 230302-43-9P 451470-98-7P  
 451470-99-8P 451471-00-4P 451471-01-5P  
 451471-02-6P 451471-03-7P 451471-04-8P  
 451471-05-9P 451471-06-0P 451471-07-1P  
 451471-08-2P 451471-10-6P 451471-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis and properties of adducts of hindered amine and  
 2-hydroxyphenylbenzotriazole as polymer stabilizers)


RN 230302-42-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 153976-86-4


CMF C18 H14 Cl N7 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 230302-43-9 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)


CM 1

CRN 153976-87-5  
CMF C18 H13 Cl2 N7 O2



CM 2


CRN 80-62-6  
CMF C5 H8 O2



RN 451470-98-7 CAPLUS  
CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-[5-[[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]-4-nitrophenol (9CI) (CA INDEX NAME)


CM 1


CRN 451470-91-0  
CMF C18 H13 Cl N8 O4



CM 2

CRN 80-62-6  
CMF C5 H8 O2






RN 451470-99-8 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-nitro-2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI)  
(CA INDEX NAME)

CM 1

CRN 451470-97-6


CMF C28 H33 N9 O5



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 451471-00-4 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-chloro-2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI)  
(CA INDEX NAME)

CM 1

CRN 451470-96-5


CMF C28 H33 Cl N8 O3



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 451471-01-5 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-[5-[[4-[(1,2,2,6,6-pentamethyl-4-piperidinyloxy]-6-(2-propenyloxy)-  
 1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX  
 NAME)

CM 1

CRN 451470-95-4


CMF C28 H34 N8 O3



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 451471-02-6 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-1,3,5-  
triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 451470-92-1


CMF C27 H32 N8 O3



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 451471-03-7 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-chloro-2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-  
piperidinyl)oxy]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol  
(9CI) (CA INDEX NAME)


CM 1

CRN 451470-93-2

CMF C27 H31 Cl N8 O3




CM 2


CRN 80-62-6  
CMF C5 H8 O2

RN 451471-04-8 CAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 4-nitro-2-[5-[[4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-  
 piperidinyl)oxy]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]phenol  
 (9CI) (CA INDEX NAME)

CM 1

CRN 451470-94-3  
CMF C27 H31 N9 O5


CM 2

CRN 80-62-6  
CMF C5 H8 O2

RN 451471-05-9 CAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-chloro-4-(2-propenyloxy)-6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-  
 1,3,5-triazine and 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-  
 yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1


CRN 219320-48-6  
CMF C15 H23 Cl N4 O2



CM 2

CRN 153976-86-4


CMF C18 H14 Cl N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 451471-06-0 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]phenol and 2-chloro-4-(2-propenyloxy)-6-[(2,2,6,6-  
 tetramethyl-4-piperidinyl)oxy]-1,3,5-triazine (9CI) (CA INDEX NAME)

CM 1

CRN 219320-48-6


CMF C15 H23 Cl N4 O2



CM 2

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 451471-07-1 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-chloro-4-((2-propenyloxy)-6-((2,2,6,6-tetramethyl-4-piperidinyloxy)-  
 1,3,5-triazine and 2-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]  
 amino]-2H-benzotriazol-2-yl]-4-nitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 451470-91-0


CMF C18 H13 Cl N8 O4



CM 2


CRN 219320-48-6

CMF C15 H23 Cl N4 O2



CM 3

CRN 80-62-6  
CMF C5 H8 O2




RN 451471-08-2 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-chloro-4-[(1,2,2,6,6-pentamethyl-4-piperidinyloxy)-6-(2-propenyloxy)-  
1,3,5-triazine and 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-  
yl]amino]-2H-benzotriazol-2-yl]-4-nitrophenol (9CI) (CA INDEX NAME)


CM 1

CRN 451470-91-0  
CMF C18 H13 Cl N8 O4



CM 2


CRN 399017-97-1  
CMF C16 H25 Cl N4 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 451471-10-6 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
2-chloro-4-[(1,2,2,6,6-pentamethyl-4-piperidinyloxy]-6-(2-propenyloxy)-  
1,3,5-triazine and 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-  
yl]amino]-2H-benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 399017-97-1


CMF C16 H25 Cl N4 O2



CM 2

CRN 153976-86-4


CMF C18 H14 Cl N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




RN 451471-11-7 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]phenol and 2-chloro-4-[(1,2,2,6,6-pentamethyl-4-  
piperidinyl)oxy]-6-(2-propenyloxy)-1,3,5-triazine (9CI) (CA INDEX NAME)

CM 1

CRN 399017-97-1


CMF C16 H25 Cl N4 O2



CM 2

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2




AB The synthesis of new types of stabilizers (a combination of  
2,2,6,6-tetramethylpiperidine and 2-hydroxyphenylbenzotriazole in one  
mol.) is reported. Six polymerizable combined stabilizers as well as two


unsatd. triazinyl-2,2,6,6-tetramethylpiperidines and three unsatd. triazinyl-2-hydroxyphenylbenzotriazoles as individual stabilizers were synthesized. Their copolymers and the terpolymers of the individual stabilizers with Me methacrylate were obtained. Chem. bonding of the stabilizers in the polymer was confirmed spectrophotometrically. The influence of these additives on the photostability of the copolymers was studied. The participation of the combined stabilizers in the polymn. did not affect considerably the rate of copolymn., the mol. wt. and polydispersity of the copolymers. A significant stabilizing effect against photodegrdn. was detd.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:224458 CAPLUS  
DN 137:22080  
TI Synthesis, characterization and explosives properties of  
7-(1H-1,2,4-triazol-3-amino)-4,6-dinitrobenzofuroxan (TADNB) and  
7-(1H-1,2,3,4-tetrazol-5-amino)-4,6-dinitrobenzofuroxan (TeADNBF)  
AU Mehilal; Sikder, Arun K.; Salunke, Rajendra B.; Sikder, Nirmala  
CS High Energy Materials Research Laboratory, Pune, 411021, India  
SO Journal of Energetic Materials (2002), 20(1), 39-51  
CODEN: JOEMDK; ISSN: 0737-0652  
PB Dowden, Brodman & Devine, Inc.  
DT Journal  
LA English  
IT **435343-56-9P 435343-57-0P**  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of; in synthesis of 7-(1H-1,2,4-triazol-3-amino)-4,6-  
dinitrobenzofuroxan and 7-(1H-1,2,3,4-tetrazol-5-amino)-4,6-  
dinitrobenzofuroxan)  
RN 435343-56-9 CAPLUS  
CN 2,1,3-Benzoxadiazol-4-amine, 5,7-dinitro-N-1H-1,2,4-triazol-3-yl-, 3-oxide  
(9CI) (CA INDEX NAME)



RN 435343-57-0 CAPLUS  
CN 2,1,3-Benzoxadiazol-4-amine, 5,7-dinitro-N-1H-tetrazol-5-yl-, 3-oxide  
(9CI) (CA INDEX NAME)



AB 7-((1H-1,2,4-triazol-3-yl)amino)-4,6-dinitrobenzofuroxan and 7-((1H-1,2,3,4-tetrazol-5-yl)amino)-4,6-dinitrobenzofuroxan were synthesized by condensing 7-chloro-4,6-dinitro benzofuroxan with 3-amino-1,2,4-triazole and 5-amino-1,2,3,4-tetrazole resp. The compds. were characterized by spectral data and elemental anal. Furthermore, some of the explosive properties of these compds. have also been investigated and reported herein.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 2000:385531 CAPLUS

DN 133:84237

TI 4-[(benzo-2,1,3-thiadiazolyl-4)amino]-5,6,7,8-tetrahydrobenzothieno-(2,3-d)-pyrimidine showing anthelmintic activity in larval alveolar echinococcosis

IN Mikhailitsyn, F. S.; Kovalenko, F. P.; Kozyreva, N. P.; Dzhabarova, V. I.; Lebedeva, M. N.; Mynzhanov, M. R.; Lychko, N. D.; Bulanov, T. E.

PA Institut Meditsinskoi Parazitologii i Tropicheskoi Meditsiny im. E. I. Martynovskogo, Russia

SO Russ.

From: Izobreteniya 1998, (21), 258.

CODEN: RUXXE7

DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RU 2116309	C1	19980727	RU 1997-102130	19970213
				RU 1997-102130	19970213


IT 188550-08-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(4-[(benzo-2,1,3-thiadiazolyl-4)amino]-5,6,7,8-tetrahydrobenzothieno-(2,3-d)-pyrimidine showing anthelmintic activity in larval alveolar echinococcosis)

RN 188550-08-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4-amine, N-2,1,3-benzothiadiazol-4-yl-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



AB Title only translated.

L4 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 2000:344126 CAPLUS

DN 132:347553

TI Process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives

IN Godlewski, Michael Selden; Klopfenstein, Sean Rees; Mundla, Sreenivasa Reddy; Seibel, William Lee; Muth, Randy Stuart

PA The Procter & Gamble Company, USA

SO U.S., 20 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6066740	A	20000523	US 1997-977907	19971125
				US 1997-977907	19971125

OS CASREACT 132:347553; MARPAT 132:347553

IT **269082-92-0P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); .PREP (Preparation)

(prepn. of 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivs.)


RN 269082-92-0 CAPLUS

CN 2,1,3-Benzothiadiazol-4-amine, N-(4,5-dihydro-1H-imidazol-2-yl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 51322-69-1

CMF C9 H9 N5 S




Patel

<5/19/2003>



CM 2

CRN 64-19-7  
CMF C2 H4 O2



AB The present invention provides a process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivs. by prepg. the corresponding activated 2-thio-substituted-2-deriv. in a two-step, one-pot procedure and by further reacting yields this isolated deriv. with the appropriate amine or its salts in the presence of a proton source. The present process allows for the prepn. of 2-amino-2-imidazolines, guanidines, and 2-amino-3,4,5,6-tetrahydropyrimidines under reaction conditions that eliminate the need for lengthy, costly, or multiple low yielding steps, and highly toxic reactants. This process allows for improved yields and product purity and provides addnl. synthetic flexibility. E.g., reaction of 2,6-dichloroaniline and N-carbomethoxy-2-thiomethyl-2-imidazoline (prepn. given) gave 2-[(2,6-dichlorophenyl)amino]-2-imidazoline as its acetate salt.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 2000:37672 CAPLUS

DN 132:77676

TI Saccharide derivatives and their enzymic manufacture using electronic mediators

IN Hayade, Koji; Tsugawa, Wakako; Hamafuji, Tetsuo

PA Kokusai Shiyaku K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000014395	A2	20000118	JP 1998-187368	19980702
				JP 1998-187368	19980702

OS MARPAT 132:77676


IT 254103-37-2P

RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (enzymic manuf. of saccharide derivs. using electronic mediators)

RN 254103-37-2 CAPLUS

CN D-Allitol, 1,5-anhydro-3-deoxy-3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB OH groups of sugars is enzymically converted into other substituents in the presence of mediators. 1,5-Anhydroglucitol (I) was oxidized in the presence of .alpha.-15 D-glucoside 3-dehydrogenase (EC 1.1.99.13; of Deleya sp. .alpha.-15) and K ferricyanide (II) while electrochem. oxidizing K ferrocyanide into II at 25.degree. and 370 mV for 16 h to give 51% 3-keto-I, which was converted into 3-fluorescently labeled I in 3 steps.

L4 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1999:511157 CAPLUS

DN 131:144607

TI Preparation of benzothiadiazoles and analogs as CRF1 receptor antagonists  
IN Neumann, Bernhard Peter

PA Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft MbH

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940089	A1	19990812	WO 1999-EP622	19990201
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

CA 2318977	AA	19990812	GB 1998-2251	A	19980203
			CA 1999-2318977		19990201
			GB 1998-2251	A	19980203
AU 9932521	A1	19990823	WO 1999-EP622	W	19990201
AU 745051	B2	20020307	AU 1999-32521		19990201
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
EP 1049694	A1	20001108	EP 1999-934200		19990201
EP 1049694	B1	20020515			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO					
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
BR 9909739	A	20010320	BR 1999-9739		19990201
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
JP 2002502853	T2	20020129	JP 2000-530518		19990201
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
AT 217622	E	20020615	AT 1999-934200		19990201
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
ES 2178451	T3	20021216	ES 1999-934200		19990201
			GB 1998-2251	A	19980203
NZ 505970	A	20030328	NZ 1999-505970		19990201
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
ZA 9900800	A	19990803	ZA 1999-800		19990202
			GB 1998-2251	A	19980203
NO 2000003916	A	20000928	NO 2000-3916		20000802
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
US 2002123629	A1	20020905	US 2002-77150		20020215
			GB 1998-2251	A	19980203
			WO 1999-EP622	W	19990201
			US 2000-601463	A1	20001031

OS MARPAT 131:144607


IT 235759-69-0P 235759-70-3P 235759-72-5P  
 235759-74-7P 235759-75-8P 235759-76-9P  
 235759-77-0P 235759-78-1P 235759-79-2P  
 235759-80-5P 235759-81-6P 235759-83-8P  
 235759-84-9P 235759-85-0P 235759-86-1P  
 235759-87-2P 235759-89-4P 235759-90-7P  
 235759-91-8P 235759-92-9P 235759-93-0P  
 235759-94-1P 235759-95-2P 235759-96-3P  
 235759-97-4P 235759-98-5P 235759-99-6P  
 235760-00-6P 235760-02-8P 235760-03-9P  
 235760-04-0P 235760-05-1P 235760-06-2P  
 235760-07-3P 235760-08-4P 235760-09-5P  
 235760-10-8P 235760-21-1P 235760-22-2P  
 235760-35-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzothiadiazoles and analogs as CRF1 receptor antagonists)

RN 235759-69-0 CAPLUS


CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2,5-

dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 235759-70-3 CAPLUS

CN 4,6-Pyrimidinediamine, N-(cyclopropylmethyl)-N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235759-72-5 CAPLUS

CN 4,6-Pyrimidinediamine, N-(cyclopropylmethyl)-N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2-methyl-N-propyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 235759-71-4

CMF C20 H26 N6 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 235759-74-7 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2-methyl-N,N-dipropyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 235759-73-6

CMF C19 H26 N6 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 235759-75-8 CAPLUS

CN 4,6-Pyrimidinediamine, 5-chloro-N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235759-76-9 CAPLUS

CN 4,6-Pyrimidinediamine, 5-chloro-N-(cyclopropylmethyl)-N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235759-77-0 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-N-ethyl-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235759-78-1 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235759-79-2 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235759-80-5 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 235759-81-6 CAPLUS

CN 4,6-Pyrimidinediamine, N-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-N'-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235759-83-8 CAPLUS

CN 4,6-Pyrimidinediamine, N-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N'-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 235759-84-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)amino]-6-(dipropylamino)-2-methyl- (9CI) (CA INDEX NAME)




RN 235759-85-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(cyclopropylmethyl)propylamino]-6-[(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 235759-86-1 CAPLUS


CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N-ethyl-N,2,5-trimethyl- (9CI) (CA INDEX NAME)



RN 235759-87-2 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N,2,5-trimethyl- (9CI) (CA INDEX NAME)






RN 235759-89-4 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N,N-diethyl-2,5-dimethyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 235759-88-3

CMF C16 H18 Cl2 N6 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 235759-90-7 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N-ethyl-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235759-91-8 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235759-92-9 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235759-93-0 CAPLUS

CN 4,6-Pyrimidinediamine, N-(cyclopropylmethyl)-N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235759-94-1 CAPLUS

CN 4,6-Pyrimidinediamine, N,N-dibutyl-N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235759-95-2 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)




RN 235759-96-3 CAPLUS

CN 4,6-Pyrimidinediamine, N-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 235759-97-4 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dichloro-2,1,3-benzothiadiazol-4-yl)-N,2,5-trimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 235759-98-5 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(7-chloro-5-methyl-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235759-99-6 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(7-chloro-5-methyl-2,1,3-benzothiadiazol-4-yl)-N-(cyclopropylmethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-00-6 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5-chloro-7-methyl-2,1,3-benzothiadiazol-4-yl)-N-(cyclopropylmethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-02-8 CAPLUS


CN 4,6-Pyrimidinediamine, N'-(5-chloro-7-methyl-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 235760-03-9 CAPLUS


CN 4,6-Pyrimidinediamine, N'-(5-chloro-2,1,3-benzothiadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)






RN 235760-04-0 CAPLUS

CN 4,6-Pyrimidinediamine, 2,5-dimethyl-N'-(5-methyl-2,1,3-benzothiadiazol-4-yl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235760-05-1 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzoxadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235760-06-2 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5-chloro-7-methyl-2,1,3-benzoxadiazol-4-yl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 235760-07-3 CAPLUS

CN 4,6-Pyrimidinediamine, N-(cyclopropylmethyl)-N'-(5,7-dimethyl-2,1,3-benzoxadiazol-4-yl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-08-4 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5-chloro-7-methyl-2,1,3-benzoxadiazol-4-yl)-N-(cyclopropylmethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-09-5 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(5,7-dimethyl-2,1,3-benzoxadiazol-4-yl)-N-ethyl-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-10-8 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-N'-(5,7-dimethyl-2,1,3-benzoxadiazol-4-yl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 235760-21-1 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-N'-(4-chloro-2,1,3-benzothiadiazol-5-yl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 235760-22-2 CAPLUS

CN 4,6-Pyrimidinediamine, N'-(4-chloro-2,1,3-benzothiadiazol-5-yl)-N-(cyclopropylmethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 235760-35-7 CAPLUS

CN 2,4-Quinazolinediamine, N2-(cyclopropylmethyl)-N4-(5,7-dimethyl-2,1,3-benzothiadiazol-4-yl)-N4-propyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 235760-34-6

CMF C23 H26 N6 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




IT 235760-38-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of benzothiadiazoles and analogs as CRF1 receptor antagonists)

RN 235760-38-0 CAPLUS


CN 2,1,3-Benzothiadiazol-4-amine, N-(6-chloro-2,5-dimethyl-4-pyrimidinyl)-5,7-dimethyl- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; (aminopyrimidinyl)amino, 4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl, etc.; R1 = H or 1 or 2 of halo, alkyl, alkoxy, CF3; Z = O, S, NMe, CR2:CR2; R2 = both H or both alkyl] were prepd. Thus, 4,6-dimethyl-2,1,3-benzothiadiazole was converted in 2 steps to 4-amino-5,7-dimethyl-2,1,3-benzothiadiazole which was N-arylated by 4,6-dichloro-2,5-dimethylpyrimidine to give, after amination, title compd. II. Data for biol. activity of I were given.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1999:329730 CAPLUS


DN 131:88486

TI Synthesis and properties of copolymers of triazinylaminobenzotriazole stabilizers with methyl methacrylate


AU Konstantinova, T.; Konstantinov, Hr.; Avramov, L.

CS Department of Organic Synthesis, University of Chemical Technology and

Metallurgy (UCTM), Sofia, 1756, Bulg.  
 SO Polymer Degradation and Stability (1999), 64(2), 235-237  
 CODEN: PDSTDW; ISSN: 0141-3910  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 IT **153976-86-4 153976-87-5**  
 RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC  
 (Process); RACT (Reactant or reagent)  
 (kinetics of Me methacrylate polymn. with)  
 RN 153976-86-4 CAPLUS  
 CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




RN 153976-87-5 CAPLUS  
 CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-  
 yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



IT **230302-42-8P 230302-43-9P**  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and properties of)  
 RN 230302-42-8 CAPLUS  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1


CRN 153976-86-4  
 CMF C18 H14 Cl N7 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2




RN 230302-43-9 CAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with  
4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
benzotriazol-2-yl]phenol (9CI) (CA INDEX NAME)

CM 1

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2



AB Copolymn. of Me methacrylate with two unsatd. triazinylaminobenzotriazole  
deriv. UV stabilizers was investigated. Chem. bonding of the stabilizer  
in the polymer was confirmed spectrophotometrically. The kinetics of

copolymn. was studied. A stabilizing effect was achieved at 0.1 wt% initial concn. of the unsatd. triazinylaminobenzotriazole deriv.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1999:113672 CAPLUS

DN 130:182476

TI Preparation of heterocyclic compounds as irreversible bicyclic inhibitors of tyrosine kinases

IN Bridges, Alexander James

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906396	A1	19990211	WO 1998-US15592	19980729
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1997-54061P P	19970729
	AU 9886659	A1	19990222	AU 1998-86659	19980729
				US 1997-54061P P	19970729
				WO 1998-US15592W	19980729
	US 6153617	A	20001128	US 1999-269647	19990325
				US 1997-54061P P	19970729
				WO 1998-US15592W	19980729
	US 2003087881	A1	20030508	US 2002-272651	20021017
				US 1997-54061P P	19970729
				WO 1998-US15592W	19980729
				US 1999-269647 A3	19990325
				US 2000-656331 B1	20000906

OS MARPAT 130:182476

IT 220577-61-7P 220577-63-9P 220578-06-3P


220578-07-4P 220578-12-1P 220578-13-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)


RN 220577-61-7 CAPLUS

CN 2-Butynamide, N-[4-(2,1,3-benzothiadiazol-4-ylamino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 220577-63-9 CAPLUS


CN 2-Propenamide, N-[4-(2,1,3-benzothiadiazol-4-ylamino)[1]benzothieno[3,2-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



RN 220578-06-3 CAPLUS

CN 2-Butenediamide, N-[3-(4-morpholinyl)propyl]-N'-[4-[[2-(phenylmethyl)-2H-benzotriazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH<sub>2</sub>—Ph

RN 220578-07-4 CAPLUS

CN 2-Octenamide, 4,4-difluoro-8-(4-morpholinyl)-N-[4-[[2-(phenylmethyl)-2H-benzotriazol-5-yl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Ph

RN 220578-12-1 CAPLUS

CN 2-Propynamide, N-[4-[[2-(2-pyridinyl)-2H-benzotriazol-5-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)




RN 220578-13-2 CAPLUS

CN 2-Butynamide, N-[4-[[2-(2-pyridinyl)-2H-benzotriazol-5-yl]amino]pyrido[3,4-


Patel

&lt;5/19/2003&gt;

d]pyrimidin-6-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds., e.g. I [X = DEF, Y = SR<sub>4</sub>, etc. ; or X = SR<sub>4</sub>, etc., and Y = DEF; D = O, etc.; E = CO, etc.; F = CR<sub>1</sub>(:C):C(R<sub>5</sub>)H, etc.; a proviso is given; R<sub>1</sub> = H, halo, etc.; R<sub>5</sub> = H, halo, perfluoroalkyl, etc.; Z = indoline moiety (generic structure given), etc.; R<sub>4</sub> = H, alkyl, etc.], are prepd. This invention also provides a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical compn. that comprises a compd. that is an irreversible inhibitor of tyrosine kinases. N-[4-(6-bromo-2,3-dihydroindol-1-yl)quinazolin-6-yl]acrylamide in vitro showed IC<sub>50</sub> of 0.4 nM against epidermal growth factor receptor tyrosine kinase.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1999:22040 CAPLUS

DN 130:223557

TI Comparison of four fluorescent Edman reagents with benzofurazan structure for the detection of thiazolinone amino acid derivatives

AU Toriba, Akira; Santa, Tomofumi; Iida, Takayuki; Imai, Kazuhiro

CS Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033, Japan

SO Analyst (Cambridge, United Kingdom) (1999), 124(1), 43-48

CODEN: ANALAO; ISSN: 0003-2654

PB Royal Society of Chemistry

DT Journal

LA English

IT 180058-81-5P 201863-58-3P 221056-88-8P


221056-89-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(comparing four fluorescent, benzofurazan-based Edman reagents for the detection of thiazolinone derivs. of amino acids)

RN 180058-81-5 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[[(4S)-4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201863-58-3 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[[(4S)-4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221056-88-8 CAPLUS

CN 5(4H)-Thiazolone, 4-(2-methylpropyl)-2-[[[7-(phenylsulfonyl)-2,1,3-benzoxadiazol-4-yl]amino]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 221056-89-9 CAPLUS

CN 5(4H)-Thiazolone, 4-(2-methylpropyl)-2-[[7-(methylsulfonyl)-2,1,3-benzoxadiazol-4-yl]amino]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




GI



Patel

<5/19/2003>



AB Two newly synthesized, fluorescent, Edman reagents with the benzofurazan structures, PSBD-NCS, I (R = SO<sub>2</sub>Ph), and MSBD-NCS, I (R = SO<sub>2</sub>Me), were compared with ABD-NCS, I (R = SO<sub>2</sub>NH<sub>2</sub>), and DBD-NCS, I (R = SO<sub>2</sub>NMe<sub>2</sub>), for peptide and protein sequence anal. by the generation of fluorescent 2,1,3-benzoxadiazolylthiazolinone (TZ)-amino acids, such as II and III. The effects of the substituent group at the para position to the isothiocyanate moiety of these reagents on the rate of the cyclization/cleavage reaction, the repetitive yield and the fluorescence quantum yield and stability of TZ amino acids were investigated. MSBD-TZ-amino acids were most sensitively detected and the detection limit for MSBD-TZ-Pro, III (R = SO<sub>2</sub>Me), was 7 fmol (S/N = 3). ABD-NCS afforded the highest repetitive yield in the sequencing anal. Fewer interfering peaks were obsd. in the chromatogram with DBD-NCS.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:8188 CAPLUS  
DN 128:89993  
TI Treatment of textile fibers with UV absorbers  
IN Isharani, Jayanti V.; Hung, Willaim M.; Su, Kai C.  
PA Ciba Specialty Chemicals Corp., USA  
SO U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 354,975, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5700394	A	19971223	US 1995-372636	19950113
				US 1994-354975	19941213
	EP 717140	A2	19960619	EP 1995-810766	19951205
	EP 717140	A3	19960626		
	R: CH, DE, ES, FR, GB, IT, LI, PT				
				US 1994-354975	19941213
				US 1995-372636	19950113
	JP 08226079	A2	19960903	JP 1995-321579	19951211
				US 1994-354975	19941213
				US 1995-372636	19950113
	ZA 9510536	A	19960613	ZA 1995-10536	19951212
				US 1994-354975	19941213
	AU 9540385	A1	19960620	AU 1995-40385	19951212

BR 9505755 A 19980106

US 1994-354975 19941213  
 US 1995-372636 19950113  
 BR 1995-5755 19951212  
 US 1994-354975 19941213  
 US 1995-372636 19950113

## PATENT FAMILY INFORMATION:

FAN 1996:504134

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 717140	A2	19960619	EP 1995-810766	19951205
	EP 717140	A3	19960626		

R: CH, DE, ES, FR, GB, IT, LI, PT

US 5700394 A 19971223

US 1994-354975 19941213  
 US 1995-372636 19950113  
 US 1995-372636 19950113  
 US 1994-354975 19941213

OS MARPAT 128:89993

IT 179912-52-8


RL: NUU (Other use, unclassified); USES (Uses)

(treatment of textile fibers with triazine group-contg. UV absorbers  
 for clothing inhibiting penetration of UV radiation)

RN 179912-52-8 CAPLUS


CN Benzenesulfonic acid, 4,4'-[(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-2H-benzotriazole-5,2-diyl)]bis[3-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B



GI



AB A method for the treatment of a textile fiber to reduce the amt. of UV light passing through a fabric produced from said treated fiber comprises treating a textile fiber with 0.1 to 6.0% by wt. on the fiber, of a UV absorber I (A = radical of a UV absorber, B = radical of a UV absorber or a water-solubilizing group, X = F or Cl). Fabrics prepd. from the treated fibers are useful in making clothing which provides protection against UV radiation for skin which is covered by the clothing, esp. lightweight summer clothing.

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1997:806534 CAPLUS

DN 128:128250

TI Effect of the substituent group at the isothiocyanate moiety of Edman reagents on the racemization and fluorescence intensity of amino acids derivatized with 2,1,3-benzoxadiazolyl isothiocyanates

AU Matsunaga, Hirokazu; Santa, Tomofumi; Iida, Takayuki; Fukushima, Takeshi; Homma, Hiroshi; Imai, Kazuhiro

CS Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113, Japan

SO Analyst (Cambridge, United Kingdom) (1997), 122(9), 931-936

CODEN: ANALAO; ISSN: 0003-2654

PB Royal Society of Chemistry

DT Journal

LA English

IT 180058-81-5P 201863-56-1P 201863-58-3P

201863-61-8P 201863-64-1P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(effect of Edman reagent isothiocyanate substituent group on racemization and fluorescence intensity of amino acids derivatized with benzoxadiazolyl isothiocyanates)

RN 180058-81-5 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[[(4S)-4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201863-56-1 CAPLUS

CN 5(4H)-Thiazolone, 2-[(7-chloro-2,1,3-benzoxadiazol-4-yl)amino]-4-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201863-58-3 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[[(4S)-4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201863-61-8 CAPLUS

CN 5(4H)-Thiazolone, 2-[(7-methoxy-2,1,3-benzoxadiazol-4-yl)amino]-4-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 201863-64-1 CAPLUS

CN 5(4H)-Thiazolone, 2-[[7-(dimethylamino)-2,1,3-benzoxadiazol-4-yl]amino]-4-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB It is shown that an electron-withdrawing or -donating group at the para-position of arom. isothiocyanate significantly affects the racemization of amino acid 2,1,3-benzoxadiazolylthiazolinone derivs. I (R = SO<sub>2</sub>NMe<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, Cl, OMe, NMe<sub>2</sub>), prep'd. by derivatization of L-leucylglycine with newly synthesized benzoxadiazolyl isothiocyanates II in Edman sequence anal. A linear relationship between the logarithms of the I enantiomer ratio and the para-substituent consts. (.sigma.p) was obtained, and the D/L configuration of the amino acid residue was retained with an isothiocyanate contg. an electron-donating group at the para-position. The para-substitution effect on the racemization of phenylthiohydantoin (PTH) amino acids was also confirmed by several para-substituted phenylisothiocyanate (PITC) reagents, including nitro-PITC, chloro-PITC, PITC, methyl-PITC and methoxy-PITC. The relationship between the fluorescence intensity of I and .sigma.p was also demonstrated. When the isothiocyanate contg. an electron-donating group was used, the fluorescence intensity of I decreased while retaining the D/L configuration of the amino acid residues.

L4 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1997:618102 CAPLUS

DN 127:278208

TI Preparation of pyrimido[5,4-d]pyrimidines as tyrosine kinase signal transduction inhibitors

IN Himmelsbach, Frank; Dahmann, Georg; Von Ruden, Thomas; Metz, Thomas

PA Dr. Karl Thomae G.m.b.H., Germany

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9732882	A1	19970912	WO 1997-EP1058	19970303
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

DE 19608653	A1	19970911	DE 1996-19608653	19960306
CA 2248316	AA	19970912	DE 1996-19608653	19960306
			CA 1997-2248316	19970303
			DE 1996-19608653	19960306
AU 9719252	A1	19970922	AU 1997-19252	19970303
AU 712072	B2	19991028		
			DE 1996-19608653	19960306
			WO 1997-EP1058	19970303
EP 885227	A1	19981223	EP 1997-907067	19970303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
			DE 1996-19608653	19960306
			WO 1997-EP1058	19970303
CN 1212696	A	19990331	CN 1997-192789	19970303
			DE 1996-19608653	19960306
BR 9708004	A	19990727	BR 1997-8004	19970303
			DE 1996-19608653	19960306
			WO 1997-EP1058	19970303
JP 2000506153	T2	20000523	JP 1997-531445	19970303
			DE 1996-19608653	19960306
			WO 1997-EP1058	19970303
ZA 9701886	A	19980907	ZA 1997-1886	19970305
			DE 1996-19608653	19960306
US 5977102	A	19991102	US 1997-812002	19970305
			DE 1996-19608653	19960306
NO 9804081	A	19980904	NO 1998-4081	19980904
			DE 1996-19608653	19960306
			WO 1997-EP1058	19970303


OS MARPAT 127:278208

IT **196511-12-3P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of pyrimido[5,4-d]pyrimidines as tyrosine kinase signal transduction inhibitors)

RN 196511-12-3 CAPLUS

CN Pyrimido[5,4-d]pyrimidin-4-amine, N-2,1,3-benzothiadiazol-4-yl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; A2,A8 = H or alkyl; A4 = NRaRb or NRdRe; A6 = Rc or Rg; Ra,Rd = H or alkyl; Rb = (un)substituted Ph; Rc = azetidino, (un)substituted pyrrolidino, -piperidino, etc.; Re = 2-fluorenyl, (un)substituted phenylalkyl, heteroaryl, etc.; Rg = alkyl, (spiro)alkyleneimino, (di)(alkyl)amino, etc.] were prepd. Thus, 5-bromo-2-methylthiopyrimidine-4-carboxylic acid was aminated and the product cyclocondensed with HCONH<sub>2</sub> to give I (A2 = A8 = H) (II; A4 = OH, A6 = SMe) which was converted in 4 steps to II (A4 = 5-indolylamino, A6 = morpholino). Data for biochem. activity of I were given.

L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1997:204146 CAPLUS

DN 126:199580

TI Preparation of heterocyclyl-substituted quinazolines as protein tyrosine kinase inhibitors

IN Cockerill, George Stuart; Carter, Malcolm Clive; Mckeown, Stephen Karl; Vile, Sadie; Page, Martin John; Hudson, Alan Thomas; Barraclough, Paul; Franzmann, Karl Witold

PA Glaxo Group Limited, UK; Cockerill, George Stuart; Carter, Malcolm Clive; Mckeown, Stephen Karl; Vile, Sadie; Page, Martin John; Hudson, Alan Thomas; Barraclough, Paul; Franzmann, Karl Witold

SO PCT Int. Appl., 47 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703069	A1	19970130	WO 1996-EP3026	19960711
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
AU 9666139	A1	19970210	GB 1995-14265 A	19950713
AU 1996-66139 19960711				
GB 1995-14265 A 19950713				
EP 843671	A1	19980527	WO 1996-EP3026 W	19960711
EP 1996-925710 19960711				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
GB 1995-14265 A 19950713				
WO 1996-EP3026 W 19960711				
JP 11508906	T2	19990803	JP 1996-505503	19960711
GB 1995-14265 A 19950713				

ZA 9605935

A

19980212

WO 1996-EP3026 W 19960711

ZA 1996-5935 19960712

GB 1995-14265 A 19950713


OS MARPAT 126:199580

IT **187667-55-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of heterocyclyl-substituted quinazolines as protein tyrosine kinase inhibitors)

RN 187667-55-6 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-[2-(phenylmethyl)-2H-benzotriazol-5-yl]-  
 (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; X = N, CH; Y = OCH<sub>2</sub>, CH<sub>2</sub>O, NH, etc.; U = (un)substituted 5-10-membered mono or bicyclic ring system contg. one or more heteroatoms such as N, O, S; R<sub>1</sub>-R<sub>4</sub> = H, halo, NH<sub>2</sub>, etc.; R<sub>5</sub> = H, halo, CF<sub>3</sub>, etc.], which are protein tyrosine kinase inhibitors, and useful in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer, were prepd. Thus, reaction of 4-chloroquinazoline with 5-amino-1-benzylindole in iPrOH afforded II.HCl which showed IC<sub>50</sub> of 0.26 .mu.M against the c-erbB-2 kinase.


L4 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1997:166792 CAPLUS

Patel

&lt;5/19/2003&gt;


DN 126:233130  
TI Search for new antiparasitic agents 17. The new agent G-1697: synthesis and examination of its antiechinococcal activity  
AU Mikhailitsyn, F. S.; Kovalenko, F. P.; Kozyreva, N. P.; Dzhabarova, V. I.; Lebedeva, M. N.; Lychko, N. D.; Bulanova, T. Ye.  
CS Russia  
SO Meditsinskaya Parazitologiya i Parazitarnye Bolezni (1996), (3), 38-42  
CODEN: MPPBAB; ISSN: 0025-8326  
PB S-Info  
DT Journal  
LA Russian  
IT **188550-08-5P**, G 1697  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(benzothiadiazol G-1697: synthesis and antiechinococcal activity)  
RN 188550-08-5 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4-amine, N-2,1,3-benzothiadiazol-4-yl-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




AB The paper describes the synthesis of the new agent G-1697 which is 4-[(benzo-2,1,3-thiadiazol-4-yl)amino]-5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidine and the results of testing its acute toxicity and antiparasitic activity on a model of Echinococcus multilocularis invasion at the larval stage in cotton rats. The max. nonlethal dose of G-1697 was 4.0 g/kg for outbred mice of both sexes whose wt. was 14 - 16 g. Adult cotton rats (males) received the agent with their feed in increasing daily doses for 3 wk continuously on days 8 to 28 after infection. The daily dose of its active ingredient varied from 0.03 to 0.35 g/kg and averaged 0.12 g/kg (the mean total dose per session was 2.47 g/kg). The baseline wt. of parasitic larvocysts (PL) per animal averaged 0.28 g at the baseline. In the treated and control rats sacrificed 34 days following infection, the mean mass of PL per animal was 0.95 and 7.51 g, resp. In the cotton rats treated with G-1697, the suppressed growth index calcd. by three parameters (moderate, max., and min. mass of PL in the animals of the comparable groups after treatment with regard to the similar baseline variables) was 90.8, 91.0 and 92.7, resp., vs. the controls. Among all PL found in each animal, its death was approx. 70 - 90% in the treated rats.

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1997:51034 CAPLUS  
DN 126:131829  
TI On the copolymerization of styrene with some UV stabilizers based on triazinylaminobenzotriazole


AU Konstantinova, T.  
CS Organic Synthesis Dep., Univ. Chem. Technol. Metallurgy, Sofia, 1756, Bulg.  
SO Angewandte Makromolekulare Chemie (1996), 243, 51-55  
CODEN: ANMCBO; ISSN: 0003-3146  
PB Huethig & Wepf  
DT Journal  
LA English  
IT **153976-90-0P 153976-91-1P**  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(copolym. of styrene with UV stabilizers based on triazinylaminobenzotriazole)  
RN 153976-90-0 CAPLUS  
CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)  
  
CM 1  
  
CRN 153976-86-4  
CMF C18 H14 Cl N7 O2



CM 2  
  
CRN 100-42-5  
CMF C8 H8




RN 153976-91-1 CAPLUS  
CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)  
  
CM 1  
  
CRN 153976-87-5  
CMF C18 H13 Cl2 N7 O2



CM 2

CRN 100-42-5

CMF C8 H8




IT 153976-86-4 153976-87-5

RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)  
 (kinetics of copolymn. of styrene with UV stabilizers based on  
 triazinylaminobenzotriazole)


RN 153976-86-4 CAPLUS

CN Phenol, 2-[[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-  
 benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



RN 153976-87-5 CAPLUS

CN Phenol, 4-chloro-2-[[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-  
 yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




AB The copolymn. of styrene with 3 polymerizable UV stabilizers based on  
 triazinylaminobenzotriazole was investigated. The relationship between  
 the polymn. rate and the character of the UV stabilizer was established.  
 The general conclusion was that the presence of the UV stabilizer retarded

the polymn. of styrene, without significant effect on the mol. wt. and the thermostability of the copolymers thus obtained.


L4 ANSWER 19 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 1996:736486 CAPLUS  
 DN 126:72206  
 TI Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells  
 AU Yoshioka, Kazuaki; Saito, Mikako; Oh, Ki-Bong; Nemoto, Yasuyuki; Matsuoka, Hideaki; Natsume, Masahiro; Abe, Hiroshi  
 CS Department of Biotechnology, Tokyo University of Agriculture and Technology, Tokyo, 184, Japan  
 SO Bioscience, Biotechnology, and Biochemistry (1996), 60(11), 1899-1901  
 CODEN: BBBIEJ; ISSN: 0916-8451  
 PB Japan Society for Bioscience, Biotechnology, and Agrochemistry  
 DT Journal  
 LA English  
 IT **174844-42-9**  
 RL BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in Escherichia coli cells)  
 RN 174844-42-9 CAPLUS  
 CN .beta.-D-Glucopyranose, 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A fluorescent deriv. of D-glucose, 2-NBDG, which was previously developed for the evaluation of glucose uptake activity by living cells, was used on Escherichia coli cells and its fate after incorporation in the cells was investigated. 2-NBDG was converted to another fluorescent deriv. (2-NGDG metabolite) immediately after it was taken by E. coli cells. This 2-NBDG was then decompd. to non-fluorescent forms. 2-NBDG metabolite was decompd. into the original 2-NBDG by G6Pase with concurrent liberation of inorg. phosphate. Furthermore, FAB/MS anal. showed that its mol. wt. was 420, the same value as that of 2-NBDG 6-phosphate. These indicate 2-NBDG metabolite should be 2-NBDG 6-phosphate. Based on these results, the feasibility of 2-NBDG as a fluorescent non-toxic probe for glucose uptake activity and its application to viability assessment of various living systems are discussed.

L4 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1996:644883 CAPLUS  
DN 125:321389  
TI Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives  
AU Okada, Minoru; Yoden, Toru; Kawaminami, Eiji; Shimada, Yoshiaki; Kudoh, Masafumi; Isomura, Yasuo; Shikama, Hisataka; Fujikura, Takashi  
CS Inst. Drug Discovery Res., Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305, Japan  
SO Chemical & Pharmaceutical Bulletin (1996), 44(10), 1871-1879  
CODEN: CPBTAL; ISSN: 0009-2363  
PB Pharmaceutical Society of Japan  
DT Journal  
LA English  
IT **148869-75-4**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(4-amino-4H-1,2,4-triazole derivs. as aromatase inhibitors)  
RN 148869-75-4 CAPLUS  
CN 2,1,3-Benzoxadiazol-5-amine, N-4H-1,2,4-triazol-4-yl- (9CI) (CA INDEX NAME)



AB Various 4-N-substituted amino-4H-1,2,4-triazole derivs. were synthesized and evaluated for aromatase-inhibitory activity (in vitro) and for pregnant mare serum gonadotropin (PMSG)-induced estrogen synthesis-inhibitory activity (in vivo). The 4-(4-cyanophenyl) amino deriv. and 4-(4-nitrophenyl)amino deriv., each processing a strong electron-withdrawing group on the Ph moiety, showed potent aromatase-inhibitory activity. Structure-activity relationship studies indicated that 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole (YM511) is highly potent aromatase inhibitor with IC<sub>50</sub> values of 0.4 and 0.12 nM in in vitro expts. using rat ovary and human placenta, resp., and an in vivo ED<sub>50</sub> of 0.002 mg/kg in rats on oral administration. YM511 was also a weak inhibitor of other steroid hormone synthesis enzymes. These data suggest that YM511 is a highly selective aromatase inhibitor and may be a useful agent for the treatment of estrogen-dependent diseases such as breast cancer.

L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1996:618910 CAPLUS  
DN 126:18845  
TI Rapid Microscale Synthesis, a New Method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin Releasing Factor1 Receptor Antagonists  
AU Whitten, Jeffrey P.; Xie, Yun Feng; Erickson, Philip E.; Webb, Thomas R.; De Souza, Errol B.; Grigoriadis, Dimitri E.; McCarthy, James R.  
CS Neurocrine Biosciences, San Diego, CA, 92121, USA  
SO Journal of Medicinal Chemistry (1996), 39(22), 4354-4357  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society

DT Journal

LA English


IT 184025-02-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. by rapid microscale synthesis using robotic driven soln. phase synthesis)

RN 184025-02-3 CAPLUS

CN 1,3,5-Triazine-2,4-diamine, N-2,1,3-benzothiadiazol-4-yl-6-methyl-N'-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



GI



I

AB Potent ACTH releasing factor1 receptor antagonists, illustrated by I (R = Pr, R1 = cyclopropylmethyl) ( $K_i = 57$  nM), were obtained by synthesizing over 350 analogs of a lead mol. I (R = Me, R1 = phenethyl) ( $K_i = 2,100$  nM) with a new robotics driven soln. phase method called Rapid Microscale Synthesis (RMS). RMS provides a convenient method for the synthesis of from 25 to several hundred analogs of a biol. active mol. in a few days to a few weeks on a modified version of a com. available robot. Reaction conditions were programmed on a windows based program for a desired synthetic sequence. The robot can run several (10 to 25) multistep syntheses in parallel; addn. of reagents, extractive work ups and purity evaluation of products were carried out in series. Multimilligram quantities of products were synthesized, purity evaluated and structures confirmed. Known quantities of products were evaluated for biol. activity. Thus RMS provides a robotics driven soln. phase synthesis method as an alternative to robotics driven solid phase synthesis to prep.

analog of a biol. active mol. and increase biol. activity of new analogs in a relatively short period of time.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 1996:504134 CAPLUS  
 DN 125:145014  
 TI Treatment of textile fibers to reduce UV transmittance  
 IN Isharani, Jayanti Veljee; Hung, William Mo-Wei; Su, Kai Chiang  
 PA Ciba-Geigy A.-G., Switz.  
 SO Eur. Pat. Appl., 15 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 717140	A2	19960619	EP 1995-810766	19951205
	EP 717140	A3	19960626		
	R: CH, DE, ES, FR, GB, IT, LI, PT				
				US 1994-354975	19941213
				US 1995-372636	19950113
	US 5700394	A	19971223	US 1995-372636	19950113
				US 1994-354975	19941213

# PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN	1998:8188				
PI	US 5700394	A	19971223	US 1995-372636	19950113
	EP 717140	A2	19960619	US 1994-354975	19941213
	EP 717140	A3	19960626	EP 1995-810766	19951205
	R: CH, DE, ES, FR, GB, IT, LI, PT				
				US 1994-354975	19941213
				US 1995-372636	19950113
	JP 08226079	A2	19960903	JP 1995-321579	19951211
				US 1994-354975	19941213
				US 1995-372636	19950113
	ZA 9510536	A	19960613	ZA 1995-10536	19951212
				US 1994-354975	19941213
	AU 9540385	A1	19960620	AU 1995-40385	19951212
				US 1994-354975	19941213
				US 1995-372636	19950113
	BR 9505755	A	19980106	BR 1995-5755	19951212
				US 1994-354975	19941213
				US 1995-372636	19950113

OS MARPAT 125:145014

IT **179912-52-8**


RL: NUU (Other use, unclassified); USES (Uses)

(treatment of textile fibers to reduce UV transmittance)

RN 179912-52-8 CAPLUS


CN Benzenesulfonic acid, 4,4'-[(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-2H-benzotriazole-5,2-diyl)]bis[3-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B



GI



I

AB The title method comprises treating a textile fiber with 0.1-6.0% of UV absorber I, wherein A is the radical of a UV absorber, B is the radical of a UV absorber or is a water-solubilizing group and X is F or Cl. Fabrics prepd. from the treated fibers are useful in making clothing which provides protection against UV radiation for skin which is covered by the clothing, esp. lightweight summer clothing.

L4 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1996:455876 CAPLUS

DN 125:143248

TI Proton: A Major Factor for the Racemization and the Dehydration at the Cyclization/Cleavage Stage in the Edman Sequencing Method

AU Matsunaga, Hirokazu; Iida, Takayuki; Santa, Tomofumi; Fukushima, Takeshi; Homma, Hiroshi; Imai, Kazuhiro

CS Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113, Japan

SO Analytical Chemistry (1996), 68(17), 2850-2856

CODEN: ANCHAM; ISSN: 0003-2700

PB American Chemical Society

DT Journal

Patel

&lt;5/19/2003&gt;

LA English


IT 180058-87-1P 180058-88-2P

RL: ANT (Analyte); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); RACT (Reactant or reagent)

(protic acids in racemization and dehydration of amino acid residues during Edman sequencing)


RN 180058-87-1 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-(hydroxymethyl)-5-oxo-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 180058-88-2 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[(4,5-dihydro-4-methylene-5-oxo-2-thiazolyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 180058-79-1P 180058-80-4P 180058-81-5P

180058-82-6P 180058-83-7P 180058-84-8P

180058-85-9P 180058-86-0P 180058-89-3P


RL: ANT (Analyte); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)

(protic acids in racemization and dehydration of amino acid residues during Edman sequencing)

RN 180058-79-1 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-[2-(methylthio)ethyl]-5-oxo-2-thiazolyl]amino]-N,N-dimethyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-80-4 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-[2-(methylthio)ethyl]-5-oxo-2-thiazolyl]amino]-N,N-dimethyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-81-5 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[[(4S)-4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry..



RN 180058-82-6 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-(2-methylpropyl)-5-oxo-2-thiazolyl]amino]-N,N-dimethyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-83-7 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-5-oxo-4-(phenylmethyl)-2-thiazolyl]amino]-N,N-dimethyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-84-8 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-5-oxo-4-(phenylmethyl)-2-thiazolyl]amino]-N,N-dimethyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-85-9 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-[(4-hydroxyphenyl)methyl]-5-oxo-2-thiazolyl]amino]-N,N-dimethyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180058-86-0 CAPLUS


CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4,5-dihydro-4-[(4-hydroxyphenyl)methyl]-5-oxo-2-thiazolyl]amino]-N,N-dimethyl-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 180058-89-3 CAPLUS

CN 2,1,3-Benzoxadiazole-4-sulfonamide, 7-[[4-[(ethylthio)methyl]-4,5-dihydro-5-oxo-2-thiazolyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




GI



AB The racemization of liberated benzoxadiazolythiazolinone (DBD-TZ) amino acids I (R = amino acid side chain) during the cyclization/cleavage reaction with trifluoroacetic acid (TFA) in the Edman sequencing procedure has been carefully investigated, and evidence is presented to show conclusively that the racemization is caused by the replacement of a hydrogen atom by TFA. The fluorescent reagent II (DBD-NCS) was used for amino acid sequencing, and DBD-TZ amino acids were used for sequence and configuration detn. DBD-thiocarbamoylated peptides were cyclized and cleaved with deuterated TFA, and the protonated pseudomol. ions ( $M - d1 + H$ )<sup>+</sup> of DBD-TZ amino acids were detected by LC/MS. Furthermore, in the reaction kinetics study, the authors confirmed that the replacement reaction by TFA correlated sufficiently with the racemization of DBD-TZ amino acids. For the purpose of retaining D/L-amino acid configuration in sequencing, an aprotic acid, i.e., the Lewis acid BF<sub>3</sub>, was used for the cyclization/cleavage reaction. When BF<sub>3</sub> was used, the derivatized DBD-TZ amino acid was scarcely racemized under cyclization/cleavage conditions. Using this method, amino acid sequencing of H-D-Phe-Met-Arg-Phe-NH<sub>2</sub> could be performed, retaining the D/L-configuration of the amino acid residues.


L4 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1996:131258 CAPLUS  
DN 124:225510  
TI A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli  
AU Yoshioka, Kazuaki; Takahashi, Hirokazu; Homma, Tomoo; Saito, Mikako; Oh, Ki-Bong; Nemoto, Yasushi; Matsuoka, Hideaki  
CS Department of Biotechnology, Tokyo University of Agriculture and Technology, Koganei, Tokyo, 184, Japan  
SO Biochimica et Biophysica Acta (1996), 1289(1), 5-9  
CODEN: BBACAQ; ISSN: 0006-3002  
PB Elsevier  
DT Journal  
LA English  
IT **174844-42-9P 174844-43-0P**  
RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fluorescent deriv. of glucose for detn. of glucose uptake activity of Escherichia coli)  
RN 174844-42-9 CAPLUS  
CN .beta.-D-Glucopyranose, 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174844-43-0 CAPLUS  
CN .alpha.-D-Glucopyranose, 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A novel fluorescent deriv. of glucose was synthesized by reacting D-glucosamine and NBD-Cl. The TLC anal. of the reaction mixt. showed the generation of a single spot with intense fluorescence ( $\lambda_{\text{Ex}} = 475$  nm,  $\lambda_{\text{Em}} = 550$  nm). The obtained novel fluorescent product, which was identified as 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) by  $^1\text{H-NMR}$  and FAB-MS spectrometries, was applied to the assessment of the glucose uptake activity of *Escherichia coli* B. The 2-NBDG accumulated in living cells and not in dead cells. The uptake of 2-NBDG was competitively inhibited by D-glucose and not by L-glucose, which suggested the involvement of the glucose transporting system in the uptake of 2-NBDG. The 2-NBDG taken into the cytoplasm of *E. coli* cells was supposedly converted into another deriv. in the glucose metabolic pathway.

L4 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1996:117837 CAPLUS

DN 124:176111

TI Preparation of tizanidine

IN Ishikura, Masatoshi; Ueda, Yutaka; Kobayashi, Kazuhiko

PA Toyo Pharma Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07267950	A2	19951017	JP 1994-83922	19940330
				JP 1994-83922	19940330


OS CASREACT 124:176111; MARPAT 124:176111

IT **173532-15-5P 173532-16-6P 173590-89-1P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of tizanidine)


RN 173532-15-5 CAPLUS

CN 1H-Imidazol-2-amine, 1-acetyl-N-(5-chloro-2,1,3-benzothiadiazol-4-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 173532-16-6 CAPLUS

CN 1H-Imidazole-1-carboxylic acid, 2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-4,5-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 173590-89-1 CAPLUS


CN 1H-Imidazole-2-amine, N-(5-chloro-2,1,3-benzothiadiazol-4-yl)-4,5-dihydro-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)



GI



II



III

AB Tizanidine (I) is prepd. from benzothiazole deriv. II and imidazolidinone deriv. III [R = alkyl, etc.]. Thus, a mixt. of II and III [R = methyl] in POCl<sub>3</sub> was stirred at 60.degree. for 48 h; after evapn. of POCl<sub>3</sub>, MeOH was added, and the resulting mixt. was refluxed for 3 h to give, after workup, 83% I.

L4 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1996:115121 CAPLUS

DN 124:146172

TI Preparation of tizanidine

IN Imai, Eiji; Nakaoku, Shozo; Fushimi, Koshiro

PA Taiyo Pharma Ind, Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07258251	A2	19951009	JP 1994-71309	19940317
				JP 1994-71309	19940317


OS CASREACT 124:146172; MARPAT 124:146172

IT 173532-15-5P 173532-16-6P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of tizanidine)


RN 173532-15-5 CAPLUS


CN 1H-Imidazol-2-amine, 1-acetyl-N-(5-chloro-2,1,3-benzothiadiazol-4-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 173532-16-6 CAPLUS

CN 1H-Imidazole-1-carboxylic acid, 2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-4,5-dihydro-, ethyl ester (9CI) (CA INDEX NAME)





GI



II

AB Tizanidine (I) is prepd. from benzothiadiazole II and imidazolidone. Thus, II was added to a mixt. of 1-acetyl-2-imidazolidone and POCl<sub>3</sub>. The reaction mixt. was stirred at 60.degree. for 10 h to give, after workup, a product which was treated with a refluxing mixt. of aq. NaOH and ethanol to give I.

L4 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1995:654981 CAPLUS

DN 123:35264

TI Barbituric acid derivatives as reactive azo dyes and process and intermediates for their preparation

IN Ehrenberg, Stefan; Engel, Aloys; Henk, Hermann

PA Bayer A.-G., Germany

SO Ger. Offen., 46 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4329421	A1	19950302	DE 1993-4329421	19930901
	EP 641838	A1	19950308	EP 1994-112968	19940819
	EP 641838	B1	19991110		
	R: CH, DE, FR, GB, LI				
	US 5502174	A	19960326	DE 1993-4329421	19930901
				US 1994-296308	19940825
				DE 1993-4329421	19930901
	JP 07102180	A2	19950418	JP 1994-229048	19940831
				DE 1993-4329421	19930901

OS MARPAT 123:35264

IT **164463-43-8P 164463-45-0P 164463-46-1P**

**164463-47-2P**


RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(yellow; prepn. of reactive azo dyes for cotton)

RN 164463-43-8 CAPLUS

CN 2H-Benzotriazole-4-sulfonic acid, 6-[[4-fluoro-6-[(2-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-[4-[[hexahydro-2,4,6-trioxo-1-(2-sulfoethyl)-5-pyrimidinyl]azo]-3-sulfophenyl]-7-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 $\text{—CH}_2\text{—CH}_2\text{—SO}_3\text{H}$ 


RN 164463-45-0 CAPLUS

CN 2H-Benzotriazole-4-sulfonic acid, 6-[[4-chloro-6-[(2-methoxy-5-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-[4-[[hexahydro-2,4,6-trioxo-1-(2-sulfoethyl)-5-pyrimidinyl]azo]-3-sulfophenyl]-7-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 164463-46-1 CAPLUS

CN 2H-Benzotriazole-4-sulfonic acid, 2-[4-[[1,3-bis(3-hydroxypropyl)hexahydro-2,4,6-trioxo-5-pyrimidinyl]azo]-3-sulfophenyl]-6-[[4-fluoro-6-[[3-[[[2-(sulfooxy)ethyl]sulfonyl]methyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-7-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 164463-47-2 CAPLUS

CN 2H-Benzotriazole-4-sulfonic acid, 6-[[4-fluoro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]amino]-7-methyl-2-[3-sulfo-4-[[hexahydro-2,4,6-trioxo-1-(2-sulfoethyl)-5-pyrimidinyl]azo]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—CH<sub>2</sub>—SO<sub>3</sub>H

GI



AB The dyes, with an azo linkage to the 5-position of a barbituric acid ring, show improved soly. and properties facilitating their synthesis. Thus, 4-HO<sub>3</sub>SOCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> was diazotized and coupled with 1-(2-sulfoethyl)barbituric acid at pH 5-7 to give I, a greenish yellow dye for cotton.

L4 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1995:332746 CAPLUS

DN 122:110194

TI Synthesis of N,N'-bis(2,4-dinitrobenzofuroxanyl)-3,5-dinitro-2,6-diaminopyridine

AU Wang, NaiXing; Chen, Boren; Ou, Yuxiang

CS Dep. Chem. Eng., Beijing Inst. Technol., Beijing, 100081, Peop. Rep. China

SO Propellants, Explosives, Pyrotechnics (1994), 19(6), 300-1

CODEN: PEPYD5; ISSN: 0721-3115

PB VCH

DT Journal

LA English


IT 157143-51-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(formation and properties of)

RN 157143-51-6 CAPLUS

CN 2,6-Pyridinediamine, N,N'-bis(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro- (9CI) (CA INDEX NAME)



AB N,N'-Bis(2,4-dinitrobenzofuroxanyl)-3,5-dinitro-2,6-diaminopyridine (I) was synthesized from 2,6-diaminopyridine and trinitrodichlorobenzene in 4 steps. The structure of I was detd. by elemental anal., IR, <sup>1</sup>H-NMR, and mass-spectral techniques.

L4 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1995:23238 CAPLUS

DN 122:31545

TI Preparation of aminoquinazolines useful in the treatment of cancer

IN Barker, Andrew John; Brown, Dearg Sutherland

PA Zeneca, UK

SO Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 602851	A1	19940622	EP 1993-309680	19931203
	EP 602851	B1	19961009		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9350728	A1	19940623	GB 1992-25765	A 19921210
	AU 664496	B2	19951116	GB 1993-10248	A 19930518
				AU 1993-50728	19931116
				GB 1992-25765	A 19921210
				GB 1993-10248	A 19930518
	ZA 9308594	A	19940610	ZA 1993-8594	19931117
				GB 1992-25765	A 19921210
	CA 2103383	AA	19940611	CA 1993-2103383	19931118
				GB 1992-25765	A 19921210
				GB 1993-10248	A 19930518

IL 107678	A1	19990312	IL 1993-107678	19931119
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
HU 65622	A2	19940728	HU 1993-3328	19931124
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
FI 9305431	A	19940611	FI 1993-5431	19931203
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
AT 143956	E	19961015	AT 1993-309680	19931203
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
ES 2093367	T3	19961216	ES 1993-309680	19931203
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
CZ 283612	B6	19980513	CZ 1993-2651	19931206
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
NO 9304504	A	19940613	NO 1993-4504	19931209
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
JP 06336481	A2	19941206	JP 1993-309184	19931209
JP 3330706	B2	20020930		
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
CN 1094043	A	19941026	CN 1993-120872	19931210
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518
US 5580870	A	19961203	US 1993-164725	19931210
			GB 1992-25765	A 19921210
			GB 1993-10248	A 19930518


OS MARPAT 122:31545

IT **159737-64-1P 159768-30-6P 159768-47-5P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as anticancer agent)

RN 159737-64-1 CAPLUS

CN 4-Quinazolinamine, N-2,1,3-benzothiadiazol-4-yl-6,7-dimethoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)




HCl



● HCl

RN 159768-30-6 CAPLUS


CN 1,3-Dioxolo[4,5-g]quinazolin-8-amine, N-2,1,3-benzothiadiazol-4-yl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 159768-47-5 CAPLUS

CN 4-Quinazolinamine, N-2,1,3-benzothiadiazol-5-yl-6,7-dimethoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



AB The title compds. [I; Q = 9- or 10-membered bicyclic heterocyclic moiety contg. 1-2 N atoms; R1 = OH, NH2, ureido, hydroxyamino, trifluoromethoxy, (un)substituted C1-4 alkyl, C1-4 alkoxy, pyrrolidin-1-yl, piperidino, etc.; m = 1-3], useful in the treatment of cancer (no data), are prepd. and I-contg. formulations presented. Thus, 4-chloro-6,7-dimethoxyquinazoline was reacted with 5-aminoquinoline, producing 6,7-dimethoxy-4-(5-quinolylamino)quinazoline, m.p. > 240.degree., in 35% yield.

L4 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:655727 CAPLUS

DN 121:255727

TI Synthesis of N,N'-bis(2,4-dinitrobenzofuroxan)-3,5-dinitro-2,6-diaminopyridine

AU Wang, Naixing; Chen, Boren; Ou, Yuxiang

CS Beijing Institute Technology, College Chemical Engineering and Material Science, Beijing, 100081, Peop. Rep. China

SO Journal of Beijing Institute of Technology (English Edition) (1993), 2(1), 15-18

CODEN: JBITE5; ISSN: 1004-0579

DT Journal


LA English

IT **157143-51-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of bis(dinitrobenzofuroxanyl)dinitrodiaminopyridine)

RN 157143-51-6 CAPLUS

CN 2,6-Pyridinediamine, N,N'-bis(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro- (9CI) (CA INDEX NAME)



AB The title compd. has been synthesized from 2,6-diaminopyridine and trinitrodichlorobenzene.

L4 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:605372 CAPLUS

DN 121:205372

TI Preparation of aminopyrimidines as aromatase inhibitors

IN Okada, Minoru; Yoden, Toru; Kawaminami, Eiji; Shimada, Yoshiaki; Kudo, Masafumi; Isomura, Yasuo

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN: CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9322290	A1	19931111	WO 1993-JP548	19930427
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				JP 1992-137762	19920428
				JP 1992-234298	19920810
	AU 9340230	A1	19931129	AU 1993-40230	19930427
				JP 1992-137762	19920428
				JP 1992-234298	19920810
				WO 1993-JP548	19930427
	EP 640595	A1	19950301	EP 1993-909428	19930427
	EP 640595	B1	19990324		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				JP 1992-137762	19920428
				JP 1992-234298	19920810
				WO 1993-JP548	19930427
	AT 178056	E	19990415	AT 1993-909428	19930427
				JP 1992-137762	19920428
				JP 1992-234298	19920810


ES 2130258	T3	19990701	ES 1993-909428	19930427
			JP 1992-137762	19920428
			JP 1992-234298	19920810
CN 1079962	A	19931229	CN 1993-105330	19930428
CN 1039228	B	19980722		
			JP 1992-137762	19920428
			JP 1992-234298	19920810
US 5538976	A	19960723	US 1994-325383	19941026
			JP 1992-137762	19920428
			JP 1992-234298	19920810
			WO 1993-JP548	19930427

OS MARPAT 121:205372

IT **157911-63-2P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and reaction of, in prepn. of drug)

RN 157911-63-2 CAPLUS

CN 2,1,3-Benzoxadiazol-5-amine, N-5-pyrimidinyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The title compds. I [A = single bond, alkylene, etc.; ring B = pyrimidine, pyridazine, triazine ring; rings D and E = (substituted) aryl, etc.; a proviso is given] were prepd. I have aromatase inhibiting activity and are useful as therapeutic agents for breast cancer, endometriosis, prostatic hypertrophy, etc. Treatment of aminopyrimidine II with NaH in DMF, followed by reaction with 4-trifluoromethylbenzyl bromide, gave, after workup, title compd. III. One compd. I in vitro exhibited IC50 of 0.036 nM against aromatase. Formulations contg. I are given.

L4 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:512781 CAPLUS

DN 121:112781

TI Synthesis of N,N'-bis(2,4-dinitrobenzofuroxano)-3,5-dinitro-2,6-diaminopyridine

AU Wang, Naixing; Chen, Boren; Ou, Yuxiang

CS Coll. Chem. Eng. Mater. Sci., Beijing Inst. Technol., Beijing, 100081, Peop. Rep. China

SO Beijing Ligong Daxue Xuebao (1993), 13(4), 475-9  
 CODEN: BLXUEV; ISSN: 1001-0645


DT Journal

LA Chinese


IT **157143-51-6P**  
 RL: PREP (Preparation)  
 (explosive, synthesis and properties of)

RN 157143-51-6 CAPLUS


CN 2,6-Pyridinediamine, N,N'-bis(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro- (9CI) (CA INDEX NAME)



- AB Because of its low d., the nitro groups in 2,6-bis(picrylamino)-3,5-dinitro pyridine was replaced by benzofuroxano groups to increase its d. and detonation velocity. The introduction of aminoheterocycles in explosives can result in increased d. and decreased impact sensitivity.
- L4 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2003 ACS
- AN 1994:193200 CAPLUS
- DN 120:193200
- TI Synthesis and application of UV stabilizers for polymeric materials based on triazinylaminobenzotriazole
- AU Konstantinova, T.; Bogdanova, A.; Stanimirov, S.; Konstantinov, Hr.
- CS Dep. Org. Synth., Higher Inst. Chem. Technol., Sofia, 1756, Bulg.
- SO Polymer Degradation and Stability (1994), 43(2), 187-93  
CODEN: PDSTDW; ISSN: 0141-3910
- DT Journal
- LA English
- IT **153976-86-4P 153976-87-5P 153976-88-6P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(UV stabilizers, prepn. and characterization and polymn. of, with styrene)
- RN 153976-86-4 CAPLUS
- CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)




- RN 153976-87-5 CAPLUS
- CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



RN 153976-88-6 CAPLUS

CN 2H-Benzotriazole-5-sulfonic acid, 6-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



IT 153976-90-0P 153976-91-1P 153976-92-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and photostability of)


RN 153976-90-0 CAPLUS

CN Phenol, 2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 153976-86-4

CMF C18 H14 Cl N7 O2




CM 2

CRN 100-42-5

CMF C8 H8

H2C=CH-Ph




RN 153976-91-1 CAPLUS

CN Phenol, 4-chloro-2-[5-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 153976-87-5


CMF C18 H13 Cl2 N7 O2



CM 2

CRN 100-42-5

CMF C8 H8




RN 153976-92-2 CAPLUS

CN 2H-Benzotriazole-5-sulfonic acid, 6-[[4-chloro-6-(2-propenyloxy)-1,3,5-triazin-2-yl]amino]-2-(2-hydroxyphenyl)-, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 153976-88-6

CMF C18 H14 Cl N7 O5 S




CM 2

CRN 100-42-5  
CMF C8 H8


H<sub>2</sub>C=CH-Ph

- AB Four new compds., derivs. of triazinylaminobenzotriazole, contg. a polymerizable allyloxy group have been synthesized. The compds. were characterized by elemental anal., TLC, IR, UV/VIA, and <sup>1</sup>H NMR spectra. Polystyrene has been prepd. in the presence of the compds. Chem. bonding of the UV stabilizer in the polymer was confirmed spectrophotometrically. The spectral (absorption and fluorescence) characteristics of the compds have been investigated, showing that 45-85% of the compds. are bound. Max. stabilizing effect is achieved at 1 wt. % initial concn. of the stabilizer. A structure-photostability relationship has been sought.
- L4 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2003 ACS  
AN 1993:674585 CAPLUS  
DN 119:274585  
TI Study on field desorption mass spectra and desorption electron impact mass spectra of four new-type gunpowders  
AU Fu, Hua; Wang, Jingzun; Wu, Yi  
CS Microchem. Inst. Beijing, Beijing, 100091, Peop. Rep. China  
SO Fenxi Huaxue (1993), 21(9), 1068-70  
CODEN: FHHHDT; ISSN: 0253-3820  
DT Journal  
LA Chinese  
IT **141479-55-2**  
RL: USES (Uses)  
(gunpowder, anal. of, by field desorption and desorption electron impact mass spectrometry)  
RN 141479-55-2 CAPLUS  
CN 2,6-Pyridinediamine, N-(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro-N'-(2,4,6-trinitrophenyl)- (9CI) (CA INDEX NAME)



- AB Field-desorption and desorption-electron-impact mass spectra of four new gunpowders are given. The two methods give intense mol. ion peaks and characteristic fragment ion peaks. One sample (C<sub>17</sub>H<sub>6</sub>N<sub>12</sub>O<sub>16</sub>) is also studied by using DEIMS metastable ion technique.

L4 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 1993:563575 CAPLUS  
 DN 119:163575  
 TI Synthesis of 2-(picrylamino)-6-(2,4-dinitrobenzofurazanylamino)-3,5-dinitropyridine  
 AU Wang, Naixing; Chen, Boren; Ou, Yuxiang  
 CS Dep. Chem. Eng., Beijing Inst. Technol., Beijing, 100081, Peop. Rep. China  
 SO Yingyong Huaxue (1993), 10(3), 94-6  
 CODEN: YIHUED; ISSN: 1000-0518  
 DT Journal  
 LA Chinese  
 IT **150302-12-8P**  
 RL: PREP (Preparation)  
 (explosive, synthesis and properties of)  
 RN 150302-12-8 CAPLUS  
 CN 2,6-Pyridinediamine, N-(5,7-dinitro-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro-N'-(2,4,6-trinitrophenyl)- (9CI) (CA INDEX NAME)



AB The title explosive, which was synthesized in high yield, is an orange yellow solid with d. 1.84 g/cm<sup>3</sup>, decompn. temp. 310.degree. (measured by differential thermal anal.), detonation velocity 807.6 cm/s, and no observable wt. loss at 100.degree. for 48 h.

L4 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 1993:517256 CAPLUS  
 DN 119:117256  
 TI Preparation of triazolyl-substituted tertiary amines as aromatase inhibitors  
 IN Okada, Minoru; Kawaminami, Eiji; Yoden, Toru; Kudo, Masafumi; Isomura, Yasuo  
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9305027	A1	19930318	WO 1992-JP1089	19920827

W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, PL,  
RO, RU, SD, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF,  
BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
AU 9224874	A1	19930405	AU 1992-24874 19920827
AU 665569	B2	19960111	

			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 A 19920827
EP 641785	A1	19950308	EP 1992-918529 19920827
EP 641785	B1	19991027	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE

			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 W 19920827
HU 67249	A2	19950328	HU 1994-611 19920827
			JP 1991-248268 A 19910902

			JP 1991-344011 A 19911202
			JP 1992-505096 19920827
			JP 1991-248268 A119910902
			JP 1991-344011 A119911202
JP 2500849	B2	19960529	

			RU 1994-16190 19920827
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
RU 2124010	C1	19981227	

			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			RO 1994-319 19920827
RO 114129	B3	19990129	

			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 W 19920827
AT 186052	E	19991115	

			AT 1992-918529 19920827
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
ES 2139605	T3	20000216	

			ES 1992-918529 19920827
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
CA 2116773	C	20021210	

			CA 1992-2116773 19920827
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 W 19920827
CN 1069974	A	19930317	

			CN 1992-110016 19920902
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
US 5674886	A	19971007	

			US 1994-199180 19940224
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 W 19920827
NO 9400686	A	19940429	

			NO 1994-686 19940228
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 A 19920827
FI 9400988	A	19940405	

			FI 1994-988 19940302
			JP 1991-248268 A 19910902
			JP 1991-344011 A 19911202
			WO 1992-JP1089 W 19920827

OS MARPAT 119:117256


IT 148869-75-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of, as intermediate for aryltriazolylamine aromatase inhibitor)

RN 148869<sup>o</sup>-75-4 CAPLUS

CN 2,1,3-Benzoxadiazol-5-amine, N-4H-1,2,4-triazol-4-yl- (9CI) (CA INDEX NAME)



GI



AB RR1NAB [I; A = single bond, lower alkylene, CO; B = lower alkyl, (un)substituted aryl, (un)substituted 5- or 6-membered ring (benzo-fused) heterocyclyl having 1-3 heteroatoms consisting of O, S, or N; R = (un)substituted aryl, (un)substituted 5- or 6-membered ring (benzo-fused) heterocyclyl having 1-3 heteroatoms consisting of O, S, or N; R1 = 4H-1,2,4-, 1H-1,2,4-, or 1H-1,2,3-triazolyl], useful for the treatment of estrogen-related diseases such as breast cancer, mastopathy, endometriosis, prostatomegaly, myoma of the uterus, and cancer of uterus body, are prepd. Thus, MeCN, 4-[N-(4-nitrophenyl)amino]-4H-1,2,4-triazole, 4-bromobenzyl bromide, and K<sub>2</sub>CO<sub>3</sub> were stirred at room temp. for 3 h to give II (X = NO<sub>2</sub>, X<sub>1</sub> = Br) which in vitro showed IC<sub>50</sub> of 0.03 nM against aromatase in human placenta-derived microsome. A tablet formulation contg. II (X = cyano, X<sub>1</sub> = Br) was given. A total of 75 I were prepd.

L4 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1993:8954 CAPLUS

DN 118:8954

TI Synthesis of N-2,4,6-trinitrophenyl-N'-2,4-dinitrobenzofuroxano-3,5-dinitro-2,6-diaminopyridine

AU Wang, Naixing; Chen, Boren; Ou, Yuxiang

CS Dep. Chem. Eng., Beijing Inst. Technol., Beijing, 10081, Peop. Rep. China

SO Propellants, Explosives, Pyrotechnics (1992), 17(5), 265-6

CODEN: PEPYD5; ISSN: 0721-3115

DT Journal

LA English


IT 141479-55-2P

RL: PREP (Preparation)

(prepn. and structure detn. and detonation properties of)

RN 141479-55-2 CAPLUS

CN 2,6-Pyridinediamine, N-(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro-N'-(2,4,6-trinitrophenyl)- (9CI) (CA INDEX NAME)



AB N-2,4,6-Trinitrophenyl-N'-2,4-dinitrobenzofuroxano-3,5-dinitro-2,6-diaminopyridine (I) was synthesized from 2,6-diaminopyridine and dinitrodichlorobenzene as well as 2,4,6-trinitrochlorobenzene. The structure was verified by elemental anal., IR, NMR, and mass spectroscopies. I had a detonation velocity of 8179.5 m/s and no wt. loss at 100.degree. for 48 h.

L4 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1992:448554 CAPLUS

DN 117:48554

TI Preparation of 1-(4-biphenyl)benzimidazoles as angiotensin II antagonists

IN Narr, Berthold; Huel, Norbert; Van Meel, Jacques; Wienen, Wolfgang; Entzeroth, Michael; Ries, Uwe

PA Thomae, Dr. Karl, G.m.b.H., Germany

SO Eur. Pat. Appl., 72 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 468470	A1	19920129	EP 1991-112404	19910722
	EP 468470	B1	19970416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4023369	A1	19920130	DE 1990-4023369A	19900723
	DE 4031287	A1	19920409	DE 1990-4031287A	19901004
	DE 4105324	A1	19920827	DE 1991-4105324A	19910220
	SU 1836357	A3	19930823	SU 1991-5001010	19910704
				DE 1990-4023369A	19900723
				DE 1990-4031287A	19901004
				DE 1991-4105324A	19910220
	CA 2047496	AA	19920124	CA 1991-2047496	19910722

CA 2047496	C	20011023	DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
FI 9103503	A	19920124	FI 1991-3503 19910722
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
NO 9102859	A	19920124	NO 1991-2859 19910722
NO 178927	B	19960325	
NO 178927	C	19960703	
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
HU 58298	A2	19920228	HU 1991-2456 19910722
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
JP 04253966	A2	19920909	JP 1991-181033 19910722
JP 2539113	B2	19961002	
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
ZA 9105717	A	19930331	ZA 1991-5717 19910722
			DE 1990-4023369A 19900723
AT 151766	E	19970515	AT 1991-112404 19910722
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
ES 2100907	T3	19970701	ES 1991-112404 19910722
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
AU 9181227	A1	19920130	AU 1991-81227 19910723
AU 640505	B2	19930826	
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
IL 98933	A1	19951231	IL 1991-98933 19910723
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
US 5385925	A	19950131	US 1994-220472 19940330
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
US 5587393	A	19961224	US 1991-732868 B1 19910719
			US 1994-299693 19940901
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
			US 1991-732868 B1 19910719
			US 1994-220472 A3 19940330
US 5684029	A	19971104	US 1996-603773 19960220
			DE 1990-4023369A 19900723
			DE 1990-4031287A 19901004
			DE 1991-4105324A 19910220
			US 1991-732868 B1 19910719

US 1994-220472 A319940330

US 1994-299693 A319940901


OS MARPAT 117:48554

IT **141838-16-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as angiotensin II antagonist)

RN 141838-16-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




GI




AB Title compds. [I; R1 = tetrahydrobenzimidazolyl, imidazopyridyl, (substituted) benzimidazolyl, benzoxazolyl, etc.; R2 = H, (S-interrupted) alkyl; R3 = carboxy, cyano, tetrazolyl, 1-triphenylmethyltetrazolyl, alkoxycarbonyl; R4 = H, F, Cl, Br], and their isomeric mixts. and salts, were prepd. Thus, 2-propyl-5-(1-methylbenzimidazol-2-yl)benzimidazole (prepn. from Me 3,4-diaminobenzoate.2HCl given) and tert-Bu 4'-bromomethylbiphenyl-2-carboxylate were stirred 15 h with KOCMe3 in Me2SO to give 70% coupling products, which were treated with CF3CO2H in CH2Cl2 to give a mixt. of 4'-[[2-propyl-5-(1-methylbenzimidazol-2-yl)benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid and 4'-[[2-propyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid. I antagonized angiotensin II in rats with pA2 values of 6.0-7.5. I, at up to 30 mg/kg i.v., were without

toxic side effects, e.g., neg. inotropic activity.

L4 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2003 ACS  
 AN 1992:235527 CAPLUS  
 DN 116:235527  
 TI Synthesis of N-2,4,6-trinitrophenyl-N'-2,4-dinitrobenzofuroxan-3,5-dinitro-2,6-diaminopyridine  
 AU Wang, Naixing; Chen, Boren; Ou, Yuxiang  
 CS Dep. Chem. Eng., Beijing Inst. Technol., Beijing, Peop. Rep. China  
 SO Kogyo Kayaku (1992), 53(1), 22-4  
 CODEN: KOKYBR; ISSN: 0368-6450  
 DT Journal  
 LA English  
 IT **141479-55-2P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as explosive)  
 RN 141479-55-2 CAPLUS  
 CN 2,6-Pyridinediamine, N-(5,7-dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)-3,5-dinitro-N'-(2,4,6-trinitrophenyl)- (9CI) (CA INDEX NAME)



GI



I

AB The title compd. (I), useful as explosive, was prepd. from 2,6-diaminopyridine, dinitrodichlorobenzene, and 2,4,6-trinitrochlorobenzene and its structure was detd. by elemental anal., IR, 1H-NMR, and MS spectroscopies.

L4 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1992:153772 CAPLUS

DN 116:153772

TI Fiber-reactive hydroxy benzotriazole compounds and perspiration- and lightfast fiber dyeings incorporating them

IN Yokogawa, Kazufumi; Kashiwano, Yutaka; Ota, Miwako; Harada, Naoki

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03241069	A2	19911028	JP 1990-35745	19900215
	JP 2946602	B2	19990906		
	JP 09188667	A2	19970722	JP 1997-2771	19900215
				JP 1990-35745	19900215

OS MARPAT 116:153772


IT **139723-52-7P 139723-56-1P**

RL: IMF (Industrial manufacture); PREP (Preparation)

(prepn. of, as fiber-reactive UV absorber for cotton dyed with reactive dyes)


RN 139723-52-7 CAPLUS

CN Benzenesulfonic acid, 3-[5-[[4-chloro-6-[ethyl[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 139723-56-1 CAPLUS


CN Benzenesulfonic acid, 3-hydroxy-4-[5-[[4-[methyl[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]amino]-6-[(4-sulfoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



GI



I



II

AB The benzotriazoles, esp. useful for enhancing the lightfastness of cotton dyed with fiber-reactive dyes, have the free-acid form I [A = (un)substituted phenylene, naphthylene, or alkylene; R1, R2 = H, alkyl, alkoxy, NO2, OH, CO2H, SO3H, Cl, Br; R3 = H, (un)substituted alkyl; W = NR4, O, (CH2)nNH; R4 = H, Me, Et; X = Cl, F, (un)substituted pyridinio, NR5R6, OR7; R5-R7 = H, (un)substituted alkyl, Ph, naphthyl, or benzyl; Y = SO2CH:CH2, SO2CH2CH2Z; Z = alkali-removable group; n = 1-4]. Cyanuric chloride was condensed with m-EtNHC6H4SO2CH2CH2OSO3H, then with 2-(4-amino-2-hydroxyphenyl)benzotriazole-6-sulfonic acid to give II,  $\lambda_{\text{max}}$  355 nm.

L4 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1992:108247 CAPLUS

DN 116:108247


TI Reactive dye mixtures and dyeing and printing cellulosic fibers therewith

IN Harada, Naoki; Yokogawa, Kazufumi; Yoshikawa, Sadanobu; Ota, Miwako;

Hashizume, Shuhei  
 PA Sumitomo Chemical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 11 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03239757	A2	19911025	JP 1990-35744	19900215
	JP 2808791	B2	19981008		
				JP 1990-35744	19900215

OS MARPAT 116:108247  
 IT **139261-23-7**  
 RL: USES (Uses)  
 (reactive dye mixts. contg., yellow laundry-fluorescent  
 brightener-safe, for cotton)  
 RN 139261-23-7 CAPLUS  
 CN Benzenesulfonic acid, 4-hydroxy-3-[5-[[4-[methyl[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]amino]-6-[(4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2H-benzotriazol-2-yl]- (9CI) (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title mixts. providing dyed fibers showing good colorfastness after laundering with detergents contg. fluorescent brighteners contain 5-95% of .gtoreq.1 hydroxybenzotriazole compd. of free-acid form I [R1, R2 = H, alkyl, alkoxy, nitro, OH, carboxy, sulfo, Cl, Br; R3 = H, (un)substituted alkyl; A = (un)substituted phenylene, naphthylene, alkylene; W = NR4, O, (CH2)1-4NH; R4 = H, Me, Et; X = Cl, F, (un)substituted pyridinio, NR5R6, OR7; R5-7 = H, (un)substituted alkyl, Ph, naphthyl, benzyl; Y = SO2CH:CH2, SO2CH2CH2Z; Z = alkali-removable group] and 5-95% other reactive dye(s). A cotton knit was dyed with 5:95 II-III to obtain a level yellow dyeing.



Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEx enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:43:15 ON 20 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:43:25 ON 20 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10077150.8

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,NH

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 12:43:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 112 TO ITERATE

100.0% PROCESSED 112 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1606 TO 2874

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 12:43:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2505 TO ITERATE

100.0% PROCESSED 2505 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 12:44:04 ON 20 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2003 VOL 138 ISS 21  
FILE LAST UPDATED: 19 May 2003 (20030519/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 2 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1997:168480 CAPLUS

DN 126:173015

TI Reduction of the toxicity of spent dye baths in cationic dyeing and manufacture of cationic dyes

IN Giera, Henry; Reichel, Felix; Berneth, Horst; Boecker, Thomas; Hassenrueck, Karin; Lange, Karl; Meisel, Karlheinrich

PA Bayer A.-G., Germany

SO Eur. Pat. Appl., 63 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 752494	A1	19970108	EP 1996-109918	19960620
	R: CH, DE, FR, GB, LI				
	DE 19524134	A1	19970109	DE 1995-19524134	19950703
	US 5725607	A	19980310	US 1996-670045	19960625
	JP 09012914	A2	19970114	JP 1996-188091	19960628
	US 5869731	A	19990209	US 1997-937289	19970925
				DE 1995-19524134	19950703
				US 1996-670045	19960625

OS MARPAT 126:173015


IT **186958-79-2P**

RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)


(dye; manuf. of cationic dyes with reduced toxicity in spent dye baths)

RN 186958-79-2 CAPLUS

CN Methanesulfonamide, N-[6-[[5-[(2-cyanoethyl)amino]-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]hydrazono]-3-(1-pyrrolidinyl)-2,4-cyclohexadien-1-ylidene]- (9CI) (CA INDEX NAME)



GI



I

AB The toxicity of spent dye baths is reduced in dyeing with cationic dyes by using cationic dyes having idealized hydration energy .gtoreq.50 kcal/mol. Based on a logarithmic correlation between the idealized hydration energy of the cationic dye and its toxicity to fish, daphne, and algae, lower toxicity dyes can be manufd. Thus, I, having COSMO idealized hydration energy 60.9 kcal/mol exhibited toxicity to daphne and algae 72 ECD50 and 19 ECD50, resp. Polyacrylonitrile fibers were dyed in a dyebath contg. I (pH 4.5-5) and exhibited an intensive neutral blue with good color fastness.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1989:567389 CAPLUS

DN 111:167389

TI Novel 3',4'-dinitrogen-substituted epipodopyllotoxin glucoside derivatives, their preparation, and use as antitumor agents

IN Vyas, Dolatrai Mohanla; Saulnier, Mark George; Kadow, John F.

PA Bristol-Myers Co., USA

SO Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 297594	A2	19890104	EP 1988-110502	19880630
	EP 297594	A3	19900725		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4874851	A	19891017	US 1987-68376	19870701
	ZA 8803762	A	19890329	US 1987-68376	19870701
				ZA 1988-3762	19880526
				US 1987-68376	19870701
	FI 8803088	A	19890102	FI 1988-3088	19880628
	FI 87357	B	19920915		
	FI 87357	C	19921228		

NO 8802849	A	19890102	US 1987-68376	19870701
NO 167807	B	19910902	NO 1988-2849	19880628
NO 167807	C	19911211		
AU 8818446	A1	19890119	US 1987-68376	19870701
AU 618536	B2	19920102	AU 1988-18446	19880628
DK 8803608	A	19890102	US 1987-68376	19870701
JP 01026592	A2	19890127	DK 1988-3608	19880630
CA 1306250	A1	19920811	US 1987-68376	19870701
			JP 1988-164102	19880630
			US 1987-68376	19870701
			CA 1988-570935	19880630
			US 1987-68376	19870701


OS MARPAT 111:167389

IT 123071-54-5P 123071-55-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and antitumor activity of)


RN 123071-54-5 CAPLUS

CN 3,5-Cyclohexadiene-1,2-dione, 5-[9-[(4,6-O-ethylidene-.beta.-D-glucopyranosyl)oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-3-methoxy-, 1,2-bis[O-(phenylmethyl)oxime], [5R-[5.alpha.,5a.beta.,8a.alpha.,9.beta.(R\*)]]-(9CI) (CA INDEX NAME)




RN 123071-55-6 CAPLUS

CN 3,5-Cyclohexadiene-1,2-dione, 5-[9-[(4,6-O-ethylidene-.beta.-D-glucopyranosyl)oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-3-methoxy-, 1,2-bis(O-methyloxime), [5R-[5.alpha.,5a.beta.,8a.alpha.,9.beta.(R\*)]]-(9CI) (CA INDEX NAME)



GI



AB The title derivs. I [Y = H, C1-8 alkyl; A = C1-10 alkyl, C2-10 alkenyl, C5-6 cycloalkyl, 2-furyl, 2-thienyl, etc.; A and Y form C5-6 cycloalkyl; B = Q1(R<sup>1</sup>, R<sup>2</sup> = C1-5 alkyl, aryl, aryl-C1-5 alkyl), Q2(R<sup>3</sup> = H; R<sup>4</sup>, R<sup>5</sup> = H, C1-5 alkanoyl, halo-C2-5 alkanoyl or R<sup>3</sup> = bond; R<sup>4</sup>, R<sup>5</sup> = CHR<sup>6</sup>; R<sup>6</sup> = aryl, substituted aryl), Q3(D = -N-; -C(R<sup>7</sup>)-; :C(R<sup>7</sup>)C(R<sup>8</sup>)-; -P(OR<sup>9</sup>)(:X)-; R<sup>7</sup>, R<sup>8</sup> = H, C1-5 alkyl; R<sup>9</sup> = C1-5 alkyl, substituted C1-5 alkyl; X = O, S)] are prepd. as antitumor agents. I (Y = H; A = Me; B = Q2; R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> = H) (II)

was prepd. by reaction of etoposide 3',4'-quinone with O-benzylhydroxylamine HCl and treatment of the product with 20% Pd hydroxide on C and hydrogenation. II at >100 mg/kg/injection showed a max. % T/C of 216 against P388 leukemia in CDF1 mice (administered i.p. on days 5 & 8 after tumor implantation).